Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
- 16 September 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (6), 1-17
- https://doi.org/10.1208/s12248-021-00628-3
Abstract
The number of viral vector-based gene therapies (GTx) continues to grow with two products (Zolgensma® and Luxturna®) approved in the USA as of March 2021. To date, the most commonly used vectors are adeno-associated virus-based (AAV). The pre-existing humoral immunity against AAV (anti-AAV antibodies) has been well described and is expected as a consequence of prior AAV exposure. Anti-AAV antibodies may present an immune barrier to successful AAV transduction and hence negatively impact clinical efficacy and may also result in adverse events (AEs) due to the formation of large immune complexes. Patients may be screened for the presence of anti-AAV antibodies, including neutralizing (NAb) and total binding antibodies (TAb) prior to treatment with the GTx. Recommendations for the development and validation of anti-AAV NAb detection methods have been presented elsewhere. This manuscript covers considerations related to anti-AAV TAb-detecting protocols, including the advantages of the use of TAb methods, selection of assay controls and reagents, and parameters critical to monitoring assay performance. This manuscript was authored by a group of scientists involved in GTx development representing eleven organizations. It is our intent to provide recommendations and guidance to industry sponsors, academic laboratories, and regulatory agencies working on AAV-based GTx viral vector modalities with the goal of achieving a more consistent approach to anti-AAV TAb assessment. Graphical abstractKeywords
This publication has 72 references indexed in Scilit:
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5Journal of General Virology, 2012
- Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophiliaGene Therapy, 2011
- Innate Immune Responses to AAV VectorsFrontiers in Microbiology, 2011
- The complement systemCell and tissue research, 2010
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationJournal of Medical Virology, 2008
- Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus VectorsJournal of Virology, 2008
- Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transductionVirology, 2007